Researchers utilized the comprehensive score for financial toxicity tool to measure self-reported financial distress among 1500-plus patients with cancer or autoimmune diseases receiving charitable copay assistance foundation support.
Hosted on MSN2h
Welch urges GOP to continue Medicare drug price negotiationsVermont Senator Peter Welch is among lawmakers urging the Trump administration not to roll back efforts that make medications less expensive.
Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations for 10 drugs whose lower prices take effect in 2026. T
The best Medicare plans for cancer patients are a Medigap Plan G from AARP and a Medicare Part D plan from Wellcare. Alternatively, if your cancer diagnosis means you can't qualify for Medigap, choose a Medicare Advantage plan from Aetna. In both cases ...
Prosecutors allege Adam Wayne Owens violated an anti-kickback statute in a scheme to provide genetic cancer testing for Medicare recipients.
WASHINGTON — Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, further complicating big decisions the Trump administration will have to make about how to cover the medications.
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.
Shares of Guardant Health (NASDAQ:GH) have increased by 5.0% in premarket trading Tuesday following the company's announcement that its Guardant Reveal test for colon cancer has been granted expanded Medicare coverage.
The hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.
The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts before President-elect Trump’s inauguration. The Centers for Medicare
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.
Guardant Health has secured Medicare coverage from Palmetto for its blood test to monitor for disease recurrence in patients with colorectal cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback